The global insomnia market is segmented based on therapy type and geography. Based on therapy type, it is bifurcated into non-pharmacological and pharmacological therapy. Non-pharmacological therapy segment is further categorized into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. Pharmacological therapy is further divided into prescription sleep aids and over-the-counter sleep aids. The market is analyzed based on region into North America, Europe, Asia-Pacific, and LAMEA.
The global insomnia market is driven by rise in demand for over-the-counter (OTC) sleep aids and emergence of therapeutics with fewer side-effects. As the drugs used for the treatment of chronic diseases have some side-effects, which could affect the patient’s quality of sleep, the rise in incidence of chronic diseases is expected to boost the market growth. Furthermore, rise in stress level among youngsters have affected the quality of sleep and increase in demand for drugs. Moreover, the rise in geriatric population, increase in healthcare expenditure, and growth in disposable income are expected to fuel the market growth. However, the side-effects caused due to excessive use of sleep medication and patent expiration of many prescription drugs in the market are expected to hinder the market growth.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates the analysis of the regional market for strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
Merck & Co. Inc.
Sanofi India Limited
Takeda Pharmaceutical Company Ltd.
Purdue Pharmaceuticals L.P.
Eisai, Co. Ltd.
Meda Consumer Healthcare Inc.
KEY MARKET SEGMENTS
By Therapy Type
Cognitive Behavioral Therapy
Other Non-pharmacological Therapy
Prescription Sleep Aids
Over-the-counter Sleep Aids
Rest of Europe
Rest of Asia-Pacific
Republic of South Africa
Rest of LAMEA
The other players of the Insomnia market include (companies not profiled in the report):
Eli Lilly and Company
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS
184.108.40.206. Emergence of therapeutics with fewer side-effects
220.127.116.11. Rise in demand for OTC sleep aids
18.104.22.168. Stressful work condition and working in shifts
22.214.171.124. Side Effects of Drugs
126.96.36.199. Rise in number of patent expiration of branded prescription drugs
188.8.131.52. Untapped Markets in Developing Economies
184.108.40.206. Presence of Large Undiagnosed Insomnia Population Pool
CHAPTER 4 INSOMNIA MARKET, BY THERAPY TYPE
4.1.1. Market size and forecast
4.2. NON-PHARMACOLOGICAL THERAPY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.5. Cognitive Behavioral Therapy
4.2.6. Medical Devices
4.2.7. Other Non-pharmacological Therapy
4.3. PHARMACOLOGICAL THERAPY
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Prescription sleep aids
4.3.5. Over-the-counter sleep aids
CHAPTER 5 INSOMNIA MARKET, BY GEOGRAPHY
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
220.127.116.11. U.S. market size and forecast
18.104.22.168. Mexico market size and forecast
22.214.171.124. Canada market size and forecast
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
126.96.36.199. UK market size and forecast
188.8.131.52. France market size and forecast
184.108.40.206. Germany market size and forecast
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
220.127.116.11. India market size and forecast
18.104.22.168. Japan market size and forecast
22.214.171.124. China market size and forecast
126.96.36.199. Rest of Asia-Pacific market size and forecast
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
188.8.131.52. Brazil market size and forecast
184.108.40.206. South Africa market size and forecast
220.127.116.11. Saudi Arabia market size and forecast
18.104.22.168. Rest of LAMEA market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. MERCK & CO. INC.
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Key strategic moves and developments
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Key strategic moves and developments
6.3. PFIZER, INC.
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Key strategic moves and developments
6.4. TAKEDA PHARMACEUTICAL COMPANY LTD.
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Key strategic moves and developments
6.5. PURDUE PHARMACEUTICALS L.P.
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Key strategic moves and developments
6.6. EISAI, CO. LTD.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Key strategic moves and developments
6.7. MEDA CONSUMER HEALTHCARE INC.
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Key strategic moves and developments
6.8. PERNIX THERAPEUTICS
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Key strategic moves and developments
6.9. VANDA PHARMACEUTICALS
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Key strategic moves and developments
6.10. ECR PHARMACEUTICALS
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Key strategic moves and developments
Insomnia is a sleep disorder where in people have problem in falling asleep or remaining asleep. The major causes of insomnia include high stress level, mental disorders, excessive consumptions of caffeine & alcohol, and other medical conditions. Insomnia is categorized into three types depending on the duration of the disorder, namely transient (few days), acute (few weeks), and chronic insomnia (few months or even years).
The global insomnia market is driven by factors such as emergence of therapeutics with fewer side-effects and rise in demand for over-the-counter (OTC) sleep aids. Few drugs that are used for the treatment of chronic diseases affect the quality of sleep; thereby, increasing the number of insomnia cases. Furthermore, rise in geriatric population and growth in disposable income are expected to boost the market growth. However, the side-effects caused due to excessive use of sleep medication and patent expiration of many prescription drugs are expected to hamper the market growth.
The pharmacological therapy segment is the highest contributor to the market growth. The non-pharmacological therapy segment is anticipated to be lucrative for market players, as these therapies cause fewer side effects as compared to drugs.
In 2016, North America accounted for the maximum contribution to the total revenue generated, owing to the high prevalence rate of insomnia, presence of high disposable income, and high demand for over-the-counter (OTC) drugs. In addition, the presence of large number of insomnia centers in this region and rise in the number of patients with chronic renal & kidney diseases are expected to boost the market growth. However, Asia-Pacific is expected to witness the highest CAGR during the study period, owing to increase in the number of people working at odd hours, rise in incidence rate of insomnia, and growth in disposable income.
Key Findings of the Insomnia Market:
The cognitive behavioral therapy segment is anticipated to grow at the highest rate during the analysis period.
The prescription drugs segment generated the highest revenue, and is expected to continue its dominance in the near future.
North America dominated the global insomnia market, and is anticipated to continue its dominance in the future.
China is expected to grow at highest CAGR in the Asia-Pacific.
The pharmacological therapy segment was the largest contributor to the market growth, in 2016.
The key companies profiled in the report include Merck & Co. Inc., Sanofi India Limited, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda Pharmaceuticals, and ECR Pharmaceuticals.
- Merck & Co. Inc.
- Sanofi India Limited
- Pfizer, Inc.
- Takeda Pharmaceutical Company Ltd.
- Purdue Pharmaceuticals L.P.
- Eisai, Co. Ltd.
- Meda Consumer Healthcare Inc.
- Pernix Therapeutics
- Vanda Pharmaceuticals
- Ecr Pharmaceuticals